Associate Professor

Department of Chemotherapy

The University of Tokyo Hospital

​

Professor Hironori Ishigami is Associate Professor in Department of Chemotherapy at The University of Tokyo Hospital. He is a surgical oncologist specializing in both surgery and chemotherapy for gastric cancer. Graduating from the University of Tokyo in 1991, Professor Ishigami completed his training in general surgery at the university hospital and its affiliated institutions. He further honed his expertise in gastric cancer surgery. In 2005, he pioneered intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis.

​

Professor Ishigami developed a treatment combining systemic chemotherapy with long-term, normothermic intraperitoneal administration of paclitaxel using an implanted port. He has designed several combination chemotherapy regimens and performed clinical trials as the principal investigator in a nationwide study group involving 40 institutions. The PHOENIX-GC trial, under his leadership, was the world’s first phase III trial to demonstrate the promising efficacy of intraperitoneal paclitaxel.

​

Professor Ishigami has challenged conversion surgery for gastric cancer patients with peritoneal metastasis who exhibit remarkable responses to combination chemotherapy. With this multidisciplinary approach, he has achieved encouraging outcomes in over 100 patients, with some survivors reaching five or even ten years.

​

Through his significant support of study groups in both Asia and Western countries, Professor Ishigami has been instrumental in facilitating the implementation of intraperitoneal chemotherapy.  This collaboration has led to the completion of several clinical trials with excellent results, with many more currently underway. He is dedicated to promoting the national and global adoption of this multidisciplinary treatment to benefit as many patients as possible.